Ketamine

Braxia Scientific Corp (CSE: BRAX) (OTC: BRAXF), a Toronto-based company that provides ketamine-assisted therapy announced that CEO Dr. Roger McIntyre and Chief Medical and Scientific Officer Dr. Josh Rosenblat have received funding of CA$918.000 (approximately $732.000) from the Canadian...

Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound. The Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic...

Novamind Inc. (OTCPink: NVMDF), a company specializing in mental health and psychedelics treatment, announced on Tuesday it intends to open four new psychiatry clinics in Utah. The clinics, operating under the Cedar Psychiatry brand, are expected to increase the company’s patient volume by...

A bill to decriminalize psychedelic substances in California is quickly moving up the legislative ladder. Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs...

This article was originally published on Reality Sandwich, and appears here with permission. Depression can be an almost intolerable burden to live with. While antidepressants help many to soothe their symptoms, many others find no relief in these substances. A decades-old drug, ...

This article by Jill Ettinger was originally published on Psychedelic Spotlight, and appears here with permission. New research out of Australia points to the benefits of ketamine therapy in reducing suicidal thoughts. The findings are published in the journal Translational Psychiatry....

Inside of a Legal Psilocybin Wellness Retreat At Benzinga, we do what we say, and we say what we do. This hands-on mentality allowed me to take a week off to experience a legal psilocybin retreat in Jamaica. The active ingredient in “magic mushrooms” is currently being researched by top...

On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry.  Horizons ETFs CEO Steve Hawkins sat down with Benzinga to discuss the listing, which brought in approximately CA$25 million ($19.4 million) in...

Mind Cure Health Inc. (CSE: MCUR), a mental health and wellness company working in the psychedelics sector, announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0...

Novamind became the latest psychedelics company to go public through a reverse take-over with Hinterland Metals Inc. The company debuted in the Canadian Securities Exchange on Tuesday under the symbol "NM." In late November, Novamind closed a private placement for CA$10 million ($7.8...

FDA Expands Psychiatric Indications For Nasal Spray Ketamine Last week, the FDA approved suicidal tendencies as additional qualifying symptoms for the application of Spravato, a ketamine nasal spray used in psychiatric treatment. Spravato is the brand name for esketamine, a chemical sibling of...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Silo Wellness To Go Public With Reverse Takeover Of Yukoterre Resources  Oregon-...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Cannabis Co. Pharmadrug Signs LOI To Purchase Dutch Psychedelics Retailer Super Smart...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Champignon Brands Buys IP Company and Adds Ketamine and New Formulations To Its Portfolio...

In February 2020, scientists in Brazil performed an open-label study on arketamine, a variant of ketamine. The pilot trial, conducted by the Federal University of Bahia, was performed on seven subjects suffering from treatment-resistant depression. It found evidence that arketamine might produce...